drugset / Trial / NCT04408755
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Timeline
- Start
- 2020-07-13
- Primary completion
- 2024-06-27
- Completion
- 2024-06-27
Outcome
Outcome not reported
Stopped (Enrollment): “The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deudextromethorphan | Unknown | 18 mg | Oral |
| Subject | Deudextromethorphan | Unknown | 42.63 mg | Oral |
| Subject | Quinidine | Small molecule | 4.9 mg | Oral |
Indications
No indication recorded.